611 related articles for article (PubMed ID: 27322737)
1. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
Gocho T; Uwagawa T; Furukawa K; Haruki K; Fujiwara Y; Iwase R; Misawa T; Ohashi T; Yanaga K
Cancer Lett; 2013 Jun; 333(1):89-95. PubMed ID: 23348695
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
Furukawa K; Iida T; Shiba H; Fujiwara Y; Uwagawa T; Shimada Y; Misawa T; Ohashi T; Yanaga K
Oncol Rep; 2010 Oct; 24(4):843-50. PubMed ID: 20811662
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
[TBL] [Abstract][Full Text] [Related]
5. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells.
Liu S; Sun X; Wang M; Hou Y; Zhan Y; Jiang Y; Liu Z; Cao X; Chen P; Liu Z; Chen X; Tao Y; Xu C; Mao J; Cheng C; Li C; Hu Y; Wang L; Chin YE; Shi Y; Siebenlist U; Zhang X
Gastroenterology; 2014 Oct; 147(4):847-859.e11. PubMed ID: 24931456
[TBL] [Abstract][Full Text] [Related]
6. Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling.
Dia VP; Gonzalez de Mejia E
Cancer Lett; 2011 Dec; 313(2):167-80. PubMed ID: 21963225
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
Shirai Y; Shiba H; Iwase R; Haruki K; Fujiwara Y; Furukawa K; Uwagawa T; Ohashi T; Yanaga K
Cancer Lett; 2016 Jan; 370(2):177-84. PubMed ID: 26546875
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
Takada N; Sugano H; Shirai Y; Saito N; Hamura R; Taniai T; Uwagawa T; Yanaga K; Ikegami T; Ohashi T; Eto K
PLoS One; 2021; 16(9):e0257019. PubMed ID: 34473771
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
Haruki K; Shiba H; Fujiwara Y; Furukawa K; Iwase R; Uwagawa T; Misawa T; Ohashi T; Yanaga K
Surgery; 2013 Sep; 154(3):468-78. PubMed ID: 23972653
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
12. DHX9 contributes to the malignant phenotypes of colorectal cancer via activating NF-κB signaling pathway.
Liu S; He L; Wu J; Wu X; Xie L; Dai W; Chen L; Xie F; Liu Z
Cell Mol Life Sci; 2021 Dec; 78(24):8261-8281. PubMed ID: 34773477
[TBL] [Abstract][Full Text] [Related]
13. A mechanistic study of the proapoptotic effect of tolfenamic acid: involvement of NF-κB activation.
Jeong JB; Yang X; Clark R; Choi J; Baek SJ; Lee SH
Carcinogenesis; 2013 Oct; 34(10):2350-60. PubMed ID: 23784084
[TBL] [Abstract][Full Text] [Related]
14. Modified apple polysaccharides suppress the migration and invasion of colorectal cancer cells induced by lipopolysaccharide.
Zhang D; Li YH; Mi M; Jiang FL; Yue ZG; Sun Y; Fan L; Meng J; Zhang X; Liu L; Mei QB
Nutr Res; 2013 Oct; 33(10):839-48. PubMed ID: 24074742
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
Furukawa K; Ohashi T; Haruki K; Fujiwara Y; Iida T; Shiba H; Uwagawa T; Kobayashi H; Yanaga K
Cancer Lett; 2011 Jul; 306(1):92-8. PubMed ID: 21482023
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
[TBL] [Abstract][Full Text] [Related]
17. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
Hua H; Chen W; Shen L; Sheng Q; Teng L
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
[TBL] [Abstract][Full Text] [Related]
19. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
20. Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells.
Yousef BA; Hassan HM; Zhang LY; Jiang ZZ
Phytomedicine; 2018 Feb; 40():140-147. PubMed ID: 29496166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
